Arnold Ventures: How A Philanthropy Helped Tip The Scales In US Drug Pricing Debate
Executive Summary
A review of grants by the organization to a range of recipients engaged in work on lowering drug prices.
You may also be interested in...
Pricing Reform Advocates Poised For ‘Rearguard Action’ By Industry If Legislation Prevails
Patient advocates are optimistic that ‘historic bill’ establishing price negotiation, inflation rebates and a spending cap in Medicare will pass into law.
ICER Extends Influence Among US Insurers With AHIP Subscription Deal
AHIP arrangement is a big win for ICER and will facilitate access to the organization’s cloud-based cost effectiveness review platform for a broad range of payers, particularly small and mid-size companies that may not have the resources to subscribe to the service on their own.
FDA, USPTO In Middle Of Congressional Tug-Of-War Over Patents And Drug Pricing
Senators Hassan and Cassidy contend the lack of coordination between the two agencies may allow patent thickets to grow. Meanwhile, Sen. Tillis is pushing the agency to refute data alleging patents are to blame for high drug prices.